Allovir Company Insiders
| ALVR Stock | USD 0.55 0.02 3.51% |
Allovir employs about 8 people. The company is managed by 12 executives with a total tenure of roughly 19 years, averaging almost 1.0 years of service per executive, having 0.67 employees per reported executive. Discussion of Allovir's management performance can provide insight into the enterprise performance.
Allovir |
Allovir Management Team Effectiveness
The company has return on total asset (ROA) of (0.3653) % which means that it has lost $0.3653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8033) %, meaning that it created substantial loss on money invested by shareholders. Allovir's management efficiency ratios could be used to measure how well Allovir manages its routine affairs as well as how well it operates its assets and liabilities.Allovir Workforce Comparison
Allovir is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2,265. Allovir adds roughly 8.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Allovir Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allovir insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allovir's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Allovir insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Brainard Diana six days ago Disposition of 8706 shares by Brainard Diana of Allovir at 0.5485 subject to Rule 16b-3 | ||
Miller Edward over two weeks ago Disposition of 2272 shares by Miller Edward of Allovir at 0.8649 subject to Rule 16b-3 | ||
Sinha Vikas over two weeks ago Disposition of 5136 shares by Sinha Vikas of Allovir at 0.8649 subject to Rule 16b-3 | ||
Miller Edward over a month ago Disposition of 766 shares by Miller Edward of Allovir at 0.7678 subject to Rule 16b-3 | ||
Miller Edward over a month ago Disposition of 635 shares by Miller Edward of Allovir at 0.779 subject to Rule 16b-3 | ||
Brett Hagen over a month ago Disposition of 301 shares by Brett Hagen of Allovir at 0.8148 subject to Rule 16b-3 | ||
Sinha Vikas over two months ago Disposition of 5251 shares by Sinha Vikas of Allovir at 0.7348 subject to Rule 16b-3 | ||
Brett Hagen over two months ago Disposition of 5045 shares by Brett Hagen of Allovir at 5.6398 subject to Rule 16b-3 |
Allovir Notable Stakeholders
An Allovir stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Allovir often face trade-offs trying to please all of them. Allovir's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Allovir's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Sonia Choi | Senior Relations | Profile | |
| Agustin MD | Advisor | Profile | |
| Dana MBA | VP Operations | Profile | |
| Ann Leen | Chief Officer | Profile | |
| Cintia PharmD | Chief Officer | Profile | |
| David Hallal | Executive Board | Profile | |
| Jeroen Beek | Consultant | Profile | |
| Diana MD | CEO Director | Profile | |
| Ugo Perlingieri | Head Operations | Profile | |
| Brett Hagen | Chief Officer | Profile | |
| Edward JD | General Secretary | Profile | |
| Dana Alexander | Senior Operations | Profile |
About Allovir Management Performance
The success or failure of an entity such as Allovir often depends on how effective the management is. Allovir management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Allovir management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Allovir management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people.
Allovir Workforce Analysis
Traditionally, organizations such as Allovir use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Allovir within its industry.Allovir Manpower Efficiency
Return on Allovir Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 23.8M | |
| Net Loss Per Executive | 15.9M | |
| Working Capital Per Employee | 19.9M | |
| Working Capital Per Executive | 13.3M |
Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.